Loading...
•
Mar 31, 2021
Wave Life Sciences Q1 2021 Earnings Report
Wave Life Sciences reported its financial results for Q1 2021 and provided a business update.
Key Takeaways
Wave Life Sciences reported a net loss of $42.5 million for the first quarter of 2021, compared to a net loss of $47.5 million for the same period in 2020. Research and development expenses were $33.4 million, and general and administrative expenses were $10.1 million. The company ended the quarter with $148.5 million in cash and cash equivalents.
Clinical trials are underway with next-generation candidates incorporating PN chemistry.
Clinical data from PN chemistry programs is expected in 2022.
In vivo ADAR editing data for the AATD program is on track for 1H 2021.
Wave expects to initiate dosing in the FOCUS-C9 and SELECT-HD clinical trials in 2021.
Forward Guidance
Wave expects that its existing cash and cash equivalents, together with expected and committed cash from its existing collaboration, will enable the company to fund its operating and capital expenditure requirements into the second quarter of 2023.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...